Dividends Inside Welcome to Dividends Inside
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Bright Minds Biosciences Inc.
DRUG
$82.78 (+ $8.24 + 11.05%)
Last updated: 2026-05-21 00:40 UTC
About the Company
Bright Minds Biosciences Inc. is a biotechnology company specializing in the development of next-generation therapeutics for neuropsychiatric disorders. The primary focus of the company is to design serotonergic compounds that have the potential to benefit patients struggling with mental health challenges. These compounds aim to modulate specific serotonin receptor subtypes, seeking to maximize therapeutic effects while minimizing adverse side effects. Bright Minds Biosciences is part of the broader pharmaceuticals and biotechnology industry, impacting sectors related to mental healthcare and treatment innovation. The company leverages advanced scientific knowledge and cutting-edge research methodologies to support advancements in the treatment of conditions such as depression, PTSD, and other mood disorders. With a mission centered on improving mental health care options, Bright Minds Biosciences plays an integral role in developing innovative solutions that address unmet medical needs in the neurology and psychiatry fields. Its work is paving the way for new therapies that could revolutionize patient care and expand the current pharmacopeia, providing hope and options for millions worldwide.
Price History
Latest News for DRUG
What Is the Probability of Success for Bright Minds Biosciences Inc (DRUG)’s Lead Drug Candidate?
Bright Minds Biosciences Inc (NASDAQ:DRUG) is among the best psychedelic stocks to buy in 2026. The company has multiple psychedelic drug candidates, including potential medicines for epilepsy. Its flagship product candidate is BMB-101, which is being developed as a treatment for absence epilepsy. On March 5, H.C. Wainwright weighed on Bright Minds Biosciences Inc. (NASDAQ:DRUG) […]
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, FDA alignment and a DSMB recommendation. Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential HELUS PHARMA REPORTS PHASE 2 HLP004 RESULTS: Helus Pharma (HELP) announced Thursday topline results from a Phase
Bright Minds Biosciences to Present at Upcoming Conferences
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences: EVENT:TD Cowen 46th Annual Health Care ConferenceDATE:Wednesday, March 4, 202
Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming Trials
Bright Minds Biosciences Inc. (NASDAQ:DRUG) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. Bright Minds Biosciences Inc. (NASDAQ:DRUG) is among the most promising stocks. TheFly reported on February 13 that Baird lowered its price target for DRUG to $126 from $142 and maintained an Outperform rating on the shares. The update […]
Canadian Securities Exchange Reports January 2026 Performance Figures
Toronto, Ontario--(Newsfile Corp. - February 17, 2026) - The Canadian Securities Exchange ("CSE" or "the Exchange") today announced market statistics for January 2026.January 2026 Operating StatisticsTrading volume of CSE listed securities totaled 2.0 billion shares;Trading value of CSE listed securities was $1.0 billion;CSE issuers completed 83 financings that raised an aggregate $446 million; andThe CSE welcomed listings from three new companies, bringing total listed securities to 737 as at..
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) today closed its recently announced public offering of 1,945,000 common shares in the capital of the Company (the “Common Shares”) at a price of US$90.00 per Common Share for gross proceeds of US$175,050,000 (the “Offering”). In connection with the Offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 291,750 Common Sh